Original Article

Progesterone/Oestradiol ratio can Better Predict Intracytoplasmic Sperm Injection Outcomes than Absolute Progesterone Level

Reda S. Hussein1,2, Ihab Elnashar1, Hisham A. Abou-Taleb1, Yulian Zhao2, Ahmed M. Abdelmagied1,2, Ahmed M. Abbas1, Osama S Abdalmageed1, Ahmed A. Abdelaleem1, Tarek A. Farghaly1, Ahmed A. Youssef1, Esraa Badran1, Mostafa N. Ibrahim1, Ahmed F Amin1

1Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt, 2Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota, USA, 3Department of Obstetrics and Gynecology, Taibah University, Medina, KSA

Background: Several parameters were proposed to predict the impact of premature luteinization on intracytoplasmic sperm injection (ICSI) outcomes such as isolated progesterone (P) level, progesterone to oocyte ratio, and progesterone/estradiol ratio (P/E2). Aim: The aim of this study is to compare the predictive value of P/E2 ratio and isolated P level on the ovulation triggering day for pregnancy outcomes in fresh GnRH antagonist ICSI cycles. Settings and Design: A retrospective cohort study conducted in a university-affiliated in vitro fertilization center between January 2017 and April 2019. Methods: The study included women who underwent their first- or second-ranked GnRH antagonist ICSI cycles with day-3 embryo transfer. P/E2 ratio was calculated as (P [ng/mL] × 1000)/E2 (pg/mL). Cutoff values of ≥1.5 ng/ml for high P and ≥0.55 for HP/E2 ratio were chosen based on the literature. Statistical Analysis: A receiver operating curve was performed to detect the predictability of serum P/E2 and P for the ongoing pregnancy rate. First, patients were divided according to either P level (low P < 1.5 ng/mL and HP ≥1.5 ng/mL) or P/E2 ratio (low P/E2 <0.55 and HP/E2 ≥ 0.55). Patients were further divided into four subgroups: (Group A: HP and HP/E2 ratio, Group B: low P and low P/E2 ratio, Group C: HP only, and Group D: HP/E2 only). A multivariate regression analysis models were used to account for the effect of the cycle confounders on the likelihood of pregnancy. Results: A total of 402 ICSI cycles were analyzed. The area under the curve was 0.67 and 0.59 for P/E2 and P, respectively. P/E2 showed a significant association with ongoing pregnancy (adjusted odds ratios [aOR]: 0.409, 95% confidence interval [CI] 0.222–0.753, P = 0.004) while HP revealed no significant predictive value (aOR: 0.542, 95% CI 0.284–1.036, P = 0.064) after the multivariate analysis. Conclusions: P elevation may not present as an independent predictor for cycle outcomes. P/E2 ratio has a better prognostic value than P alone in predicting pregnancy of GnRH antagonist cycles.

Keywords: Infertility; intracytoplasmic sperm injection, pregnancy outcomes, premature luteinisation, progesterone, progesterone/estradiol ratio

INTRODUCTION

In in-vitro fertilization (IVF) cycles, there has been a controversy about significance of the premature progesterone (P) rise during the late follicular phase,
commonly known as premature luteinization (PL) and its impact on ART outcomes. PL is broadly defined as an elevation of serum \( P \geq 1.5 \) ng/ml in the follicular phase before the trigger administration for final oocyte maturation in controlled ovarian stimulation cycles (COS).\(^{[1,2]}\)

In a meta-analysis of >60,000 IVF cycles, Venetis et al.\(^{[3]}\) concluded that PL is associated with a decreased pregnancy probability in fresh embryo transfer (ET) cycles. This detrimental effect could be explained by accelerated endometrial maturation leading to a desynchronization between embryo growth and endometrial receptivity.\(^{[4,5]}\) The success of frozen-thawed embryos originating from the cycles complicated by PL as well as the data of the oocyte donation cycles supports this judgment.\(^{[6]}\) However, there is growing evidence regarding the effect of PL on embryo or oocyte quality.\(^{[6,7]}\)

PL is not uncommon. Neither gonadotropin-releasing hormone agonist nor GnRH antagonist regimens could eliminate its risk. PL could be detected in all categories of patients undergoing COS, such as hyperresponders, normal responders, and poor responders.\(^{[8]}\) The incidence of PL was linked to different factors such as daily follicle-stimulating (FSH) hormone dosage,\(^{[2]}\) total gonadotrophin dose,\(^{[9]}\) stimulation days,\(^{[10]}\) number of retrieved oocytes, and peak estradiol level.\(^{[2]}\)

To date, an effective prevention of PL is still lacking. In the literature, several measures were suggested to reduce the incidence of PL on IVF cycles: (1) addition of corticosteroids to COS cycles in patients with higher basal P,\(^{[11]}\) (2) optimal timing of ovulation triggering,\(^{[12,13]}\) (3) step-down stimulation approach with avoidance of enhanced ovarian stimulation toward the late follicular phase,\(^{[10]}\) and recently (4) metformin.\(^{[14,15]}\) However, further well-designed studies are needed to prove their success in the prevention of PL in IVF cycles.

Different indicators were suggested for diagnosing the PL such as absolute P level, progesterone/estradiol (P/E2) ratio, P/oocyte ratios or different P levels based on the ovarian response.\(^{[16]}\) Many reports questioned the accuracy of absolute P level on the ovulation triggering day to predict the pregnancy outcomes. Instead, the use of P/E2 ratio to take into accounts the number of the developing follicles in COS cycles, was proposed.\(^{[17-19]}\)

Cetinkaya et al.\(^{[20]}\) reported that the P value on the late follicular phase is positively correlated with the number of mature follicles and peak estradiol levels. Moreover, the use of P/E2 can take into account the number of growing follicles during COS.\(^{[18,19]}\) Progesterone elevation was linked to compromised pregnancy rates in poor responders yet not in high responders.\(^{[20]}\) Hence, whether this adverse outcome is created by poor ovarian reserve or high P (HP) can be examined more precisely with the poor ovarian reserve group.\(^{[21]}\) Progesterone/estradiol ratio was purposed to be a more useful predictor for PL in the regard of differentiating the source of P production either from numerous growing mature follicles or immature dysregulated ones.\(^{[17,22]}\) However, some authors presented low sensitivity and positive predictive value for P/E2 and disputed its clinical application.\(^{[23,24]}\) Aflatoonian et al.\(^{[25]}\) revealed that neither P nor P/E2 has valid predictability for pregnancy and introduced the P to oocyte (P/oocyte) ratio to become a more efficient parameter for PL-induced adverse effects.

Our study aims to compare the predictive value of trigger day P/E2 and isolated progesterone (P) level on the ovulation triggering day for the pregnancy outcomes among GnRH antagonist cycles with day-3 ET.

**METHODS**

**Study type, setting, and duration**

This was a retrospective, cohort study performed at in a single university-affiliated IVF center after obtaining Institutional Review Board approval. All patients included in the study consented to use their anonymized data for education/research purpose. Women who underwent their first or second intracytoplasmic sperm injection (ICSI) with GnRH antagonist and day-3 fresh ET between January 2017 and April 2019 were included. The study sample was determined according to the number of patients who met the eligibility criteria during the study’s period and not on a previously calculated equation. Only levels of Anti-Müllerian hormone (AMH) ≥1 ng/ml and a basal FSH <10 mIU/mL were eligible for the study. IVF cycles involving uterine factor or surgically retrieved sperm were excluded.

**Ovarian stimulation**

Ovarian stimulation was started on either spontaneous or assigned day-2 after priming with low-dose oral contraceptive pills containing 0.03 mg of ethinyl estradiol and 0.075 mg gestodene (Gynera, Bayer Schering Pharma, Germany). Stimulation was started with 4–5 days of recombinant FSH (Gonal-F, MerkSerono Pharmaceutical, Egypt) followed by intramuscular menotropins injections (Menogon, Ferring, Germany). GnRH antagonist (InjCetrotide 0.25 mg SC daily, Merck-Serono, Germany) was added from the day when estradiol level reached ≥500 pg/mL, or the leading follicle was ≥14 mm. Gonadotropins dose was determined according to age, body mass index (BMI), ovarian reserve, and ovarian response history for patients undergoing the second ICSI trial. For
ovulation triggering either 10,000 IU human chorionic gonadotropin (Choriomon, IBSA Pharmaceutical, Egypt) or 250 µg of rHCG (Ovidrel; EMD Serono, Canada) were administered when ≥3 follicles reached a mean diameter of 17 mm. A transvaginal ultrasound-guided follicular aspiration was performed 34–36 h after the trigger.

Mature oocytes were fertilized by ICSI 6 h after the retrieval with the husband’s sperm. Embryos that reached eight-cell stage on day 3 with <20% fragmentation are defined as good quality embryos.[26] Intramuscular P (Prontogest, IBSA Pharmaceutical, Egypt) at 25 mg twice daily was used for luteal phase support after oocyte retrieval until a pregnancy test. One or two best quality embryos were transferred on day-3 after egg retrieval according to the patients’ age and embryo quality. A serum pregnancy check was done 14 days after ET.

Measurement of outcomes

The primary outcome was the ongoing pregnancy rate defined as the number of cases with pregnancy >12 weeks of gestation divided by the cycles initiated per 100. The secondary outcome was the implantation rate calculated as the number of gestational sacs observed, divided by the number of embryos transferrred.

Hormone measurements

Serum P and E2 levels were measured on a triggering day and analyzed by the Mini-Vidas technique with a sensitivity of 0.2 ng/mL (range of measurement was 0.2–40 ng/mL). Progesterone/estradiol ratio was calculated as [(P (ng/mL) × 1000)/E2 (pg/mL)]. Our hormone measurements were usually performed between 8 and 10 am to limits the diurnal variation of hormones.[27] Coefficients of variations of hormonal measurements were <3% (internal laboratory data).

Grouping of patients

A receiver operating curve analysis was performed to detect the predictability of serum P and P/E2 for pregnancy outcomes [Figure 1]. Nevertheless, the area under the curve (AUC) was insufficient to obtain an efficient cutoff level. The AUC was 0.59 for serum P and 0.67 for P/E2. Thus, we chose cutoff values of 1.5 ng/mL for serum P and 0.55 for P/E2 based on a literature review.[21] First, patients were divided into two groups according to either P level (low P (<1.5 ng/mL) or P/E2 ratio (low P/E2 <0.55 and HP/E2 ≥ 0.55). Thereafter, patients were further divided into four subgroups [Group A: HP ≥1.5 ng/mL and HP/E2 ≥0.55, Group B: low P <1.5 ng/mL and low P/E2 <0.55, Group C: HP ≥1.5 ng/mL and low P/E2 <0.55 (HP only), and Group D: low P <1.5 ng/mL and HP/E2 >0.55 (HP/E2 only)].

Statistics

The collected data were entered into a Microsoft Access database and analyzed using the Statistical Package for the Social Sciences software (SPSS Inc., Chicago, Illinois, USA, version 21). Data are presented as mean ± standard deviation or frequencies and percentages. Patient’s characteristics and cycle outcomes were compared between the groups of HP (≥1.5 ng/mL) and low P (<1.5 ng/mL) and between the groups of HP/E2 (≥0.55) and low P/E2 (<0.55) using the Student’s t-test. Univariate analysis was used to study the association between HP and HP/E2 and pregnancy outcomes. Then, a multivariate binary logistic regression model was conducted to account for the cycle covariates. Patients were subdivided into four groups to investigate further whether the P/E2 ratio can add more information over P alone. The clinical characteristics and cycle data were analyzed using the ANOVA for the continuous variables and Chi-square for categorical ones. A two-sided P < 0.05 was considered to be statistically significant.

Results

A total of 512 fresh GnRH antagonist ICSI cycles was performed during the study period, of which 402 had day-3 ET and met the eligibility criteria of our study. The most frequent causes of infertility were male factor (32.6%), unexplained infertility (23.4%), anovulatory disorders (22.6%), tuboperitoneal factors (12.5%), and combined factors (8.7%). Primary infertility was encountered in 278 (69.2%) of cases and 331 (82.3%) patients had their first ICSI trial.
The baseline characteristics and stimulation cycle data of the study groups are presented in Table 1. The cohort with $P \geq 1.5$ ng/ml achieved comparable top quality embryos and implantation rate with those having $P < 1.5$ ng/ml. Nevertheless, ongoing pregnancy rate was lower when serum $P < 1.5$ ng/ml (24% vs. 37.7%, $P = 0.029$). On the other hand, the difference was more significant between patients with low P/E2 and HP/ E2 in terms of the number of top quality embryos, implantation, and ongoing pregnancy rates (5.0 ± 2.8 vs. 3.3 ± 2.5, $P < 0.001$; 24.7% vs. 12.3%, $P < 0.001$; 42% vs. 16.6%, $P < 0.001$, respectively).

Table 2 summarizes the subgroup comparisons of P level and P/E2 ratio. As compared with low P and HP/E2 group (Group D), the group of HP and low P/E2 (Group C) yielded higher number of mature follicles, retrieved oocytes, mature oocytes, and embryos ($P < 0.01$) despite lower gonadotrophins dose used ($P = 0.023$). In addition, Group C had the highest peak estradiol level and number of good quality embryos among all groups.

The highest ongoing pregnancy rate was observed in Group B (low P and low P/E2), whereas the lowest one was in Group A (HP and HP/E2). Patients with HP/E2 and low P (Group D) had a lower pregnancy rate than those with low P and low P/E2 ratio (Group B) (21.3% vs. 42.2%, $P < 0.001$). On the contrary, pregnancy was not significantly different between the groups of HP and low P/E2 (Group C) and low P and low P/E2 (Group B) (34% vs. 42.2%, $P = 0.33$).

Table 2 also illustrates that Group C (HP and low P/ E2) and Group B (low P and low P/E2) generated the highest number of good quality day-3 embryos with a nonsignificant difference in the pairwise comparison of them ($P > 0.05$). On the other hand, the elevation of P/E2 alone (Group D) led to a similar number of good embryos compared to the rise of both P and P/ E2 ($P > 0.05$).

In unadjusted univariate analysis, both P and P/E2 showed a statistically significant effect on the ongoing pregnancy rate ($P = 0.031$, $P < 0.001$ for P and P/ E2, respectively). The multivariate logistic regression analysis model demonstrated that HP did not have a significant association with pregnancy (adjusted odds ratios [aOR]: 0.542, 95% confidence interval [CI] 0.284–1.036, $P = 0.064$), yet P/E2 still has a significant inverse effect on pregnancy (aOR: 0.409, 95% CI 0.222–0.753, $P = 0.004$) [Table 3].

A correlation analysis was performed to further investigate the patient’s profile and cycle parameters in relation to follicular P elevation [Table 4]. Taking all cycle confounders into account (age, BMI, AFC, AMH, number of mature follicles, total

### Table 1: Baseline characteristics and cycle parameters

| Characteristics                        | High P $\geq$1.5 (n=75) | Low P $<$1.5 (n=327) | $P$   | High P/E2 ratio $\geq$0.55 (n=114) | Low P/E2 ratio $<$0.55 (n=288) | $P$   |
|----------------------------------------|--------------------------|----------------------|------|-----------------------------------|-------------------------------|------|
| Age (years)                            | 31.3±4.3                 | 30.8±4.3             | 0.434| 31.9±4.9                          | 30.5±4.0                      | 0.002*|
| BMI (kg/m²)                            | 26.5±4.4                 | 28.4±4.8             | 0.003*| 26.7±4.1                          | 28.6±4.9                      | 0.001*|
| Duration of infertility (years)        | 6.7±3.3                  | 6.4±3.0              | 0.581| 6.4±3.7                           | 6.5±2.9                       | 0.851|
| AFC                                    | 16.2±9.9                 | 14.8±8.5             | 0.235| 12.6±7.9                          | 16.0±9.0                      | <0.001*|
| AMH (ng/mL)                            | 3.6±3.6                  | 3.5±2.9              | 0.905| 2.5±2.3                           | 3.9±3.2                       | <0.001*|
| Basal FSH (IU/L)                       | 6.2±2.4                  | 6.2±2.7              | 0.963| 7.4±3.2                           | 5.7±2.3                       | 0.001*|
| Total gonadotrophin dose               | 3384.7±1123.9            | 3126.8±1087.2        | 0.066| 3719.7±1312.3                     | 2959.3±916.4                  | <0.001*|
| Stimulation days                       | 11.7±1.7                 | 11.6±1.5             | 0.406| 11.7±1.8                          | 11.6±1.4                      | 0.342|
| Endometrial thickness                  | 9.6±1.7                  | 9.6±1.7              | 0.808| 8.9±1.9                           | 9.8±1.5                       | <0.001*|
| Peak estradiol                         | 3857.9±2564.1            | 2845.1±1685.87       | <0.001*| 1732.4±821.2                     | 3549.3±1983.9                 | <0.001*|
| Follicles ≥15 mm                       | 21.6±11.6                | 17.5±9.2             | 0.001*| 14.2±9.5                          | 19.8±9.4                      | <0.001*|
| Retrieved oocytes                      | 18.3±9.9                 | 14.5±7.4             | <0.001*| 12.0±8.2                          | 16.5±7.7                      | <0.001*|
| Mature oocytes                         | 13.6±7.5                 | 11.0±5.7             | <0.001*| 9.1±6.4                           | 12.5±5.8                      | <0.001*|
| Fertilized                             | 9.8±5.4                  | 8.3±4.7              | 0.020*| 6.7±4.9                           | 9.3±4.7                       | <0.001*|
| Number of good quality day-3 embryos   | 4.6±2.9                  | 4.5±2.7              | 0.872| 3.3±2.5                           | 5.0±2.8                       | 0.001*|
| Rate of top quality embryo formation   | 54.5±23.6                | 56.8±28.5            | 0.589| 57.9±39.2                         | 55.6±19.3                     | 0.051|
| Transferred embryos                    | 1.38±0.9                 | 1.74±0.6             | <0.001*| 1.45±0.8                          | 1.76±0.6                      | <0.001*|
| Implantation rate (%)                  | 18/104 (17.3)            | 126/358 (22.6)       | 0.074| 19/155 (12.3)                      | 125/507 (24.7)                | <0.001*|
| Ongoing pregnancy (%)                  | 18/75 (24)               | 122/327 (37.3)       | 0.029*| 19/114 (16.6)                      | 121/288 (42.0)                | <0.001*|

Data are presented as mean±SD or number and %. *Statistically significant difference. P=Progesterone, P/E2=Progesterone/estradiol ratio, BMI=Body mass index, AFC=Antral follicle count, AMH=Anti-Müllerian Hormone, FSH=Follicle-stimulating hormone, SD=Standard deviation.
Table 2: Subset analysis based on progesterone level and progesterone/estradiol ratio

| Characteristics                   | Group A |          | Group B |          | Group C |          | Group D |          | P        |
|-----------------------------------|---------|----------|---------|----------|---------|----------|---------|----------|----------|
| Age (years)                       | 32.3±4.5 | 30.5±4.0 | 30.3±3.8 | 31.8±5.1 | 0.05    |
| BMI (kg/m²)                       | 26.6±3.9 | 28.9±4.9 | 26.5±4.9 | 26.8±4.2 | 0.001*  |
| Duration of infertility (years)   | 6.7±3.7  | 6.4±2.9  | 6.9±2.7  | 6.2±3.7  | 0.751   |
| AFC                               | 13.6±8.8 | 15.7±8.8 | 19±10.3  | 12.1±7.3 | <0.001* |
| AMH (ng/ml)                       | 2.5±1.9  | 3.8±3.0  | 4.7±4.4  | 2.5±2.4  | <0.001* |
| Basal FSH (IU/L)                  | 6.6±2.3  | 5.7±2.2  | 5.8±2.4  | 7.7±3.4  | <0.001* |
| Total gonadotrophin dose          | 3520.9±1163.9 | 2934.3±899.6 | 3167.6±1025.9 | 3764.1±1378.2 | <0.001* |
| Stimulation days                  | 11.7±1.7 | 11.6±1.4 | 11.7±1.7 | 11.7±1.8 | 0.950   |
| Endometrial thickness (mm)        | 9.1±1.7  | 9.7±1.5  | 10.1±1.6 | 8.9±2.0  | <0.001* |
| Peak estradiol                    | 2312.9±1031.8 | 3270.4±1699.6 | 5441.4±2705.9 | 1522.3±613.9 | <0.001* |
| Follicles ≥15 mm                  | 17.7±12.5 | 19.1±9.2 | 25.6±9.6 | 12.3±7.0 | <0.001* |
| Retrieved oocytes                 | 15.0±10.8 | 15.8±7.3 | 21.5±8.1 | 10.7±6.2 | <0.001* |
| Mature oocytes                    | 11.1±7.8 | 11.9±5.5 | 16.2±6.5 | 8.3±5.4  | <0.001* |
| Fertilized                        | 8.1±5.7  | 9.0±4.6  | 11.5±4.5 | 6.1±4.3  | <0.001* |
| Number of good quality day-3 embryos | 3.3±2.7 | 4.9±2.7  | 5.9±2.7  | 3.5±2.4  | <0.001* |
| Rate of top quality embryo formation | 45.4±28.8 | 56.0±19.8 | 52.4±16.6 | 63.7±14.1 | 0.004* |
| Transferred embryos               | 1.3±0.9  | 1.8±0.5  | 1.4±0.9  | 1.5±0.8  | <0.001* |
| Implantation rate (%)             | 3/43 (6.9) | 110/450 (24.4) | 13/53 (24.5) | 17/114 (14.9) | <0.001* |
| Ongoing pregnancy (%)             | 3/33 (9.1) | 106/250 (42.2) | 13/38 (34.2) | 17/80 (21.3) | <0.001* |

Data are presented as mean±SD or number and %. *Statistical significant difference. Pairwise comparisons (when overall P<0.05): BMI: A versus B=0.03, B versus C=0.023, B versus D=0.004, AFC: A versus C=0.037, B versus D=0.008, C and D=0.001, AMH: A versus C=0.006, B versus D=0.006, C versus D=0.001, Basal FSH: B versus D=0.001, C versus D=0.002, Gonadotrophins dose: A versus B=0.009, B versus D=0.001, C versus D=0.023, Endometrial thickness: B versus D<0.001, C versus D<0.001, Peak estradiol: A versus B<0.001, A versus C=0.013, B versus D<0.001, Follicles≥13 mm: A versus C=0.002, A versus D=0.027, B versus D<0.001, C versus D=0.001, Retrieved oocytes: A versus C=0.001, B versus C=0.001, B versus D<0.001, Mature oocytes: A versus C=0.001, B versus C=0.001, B versus D<0.001, Implication rate: A versus B<0.001, A versus C=0.002, A versus D=0.001, Implantation rate: B versus C=0.001, B versus D=0.001, C versus D=0.001, Number of good quality day-3 embryos: A versus B=0.004, A versus C=0.001, B versus D<0.001, C versus D<0.001, Rate of top quality embryo formation: A versus D=0.003, Transferred embryos: A versus B<0.001, B versus C=0.001, B versus D<0.001, Fertilized: A versus C=0.013, B versus C=0.017, B versus D=0.001, Number of good quality day-3 embryos: A versus B=0.004, A versus C=0.001, B versus D<0.001, C versus D<0.001, Rate of top quality embryo formation: A versus D=0.003, Transferred embryos: A versus B<0.001, B versus C=0.001, B versus D<0.001, C versus D=0.001, Fertilized: A versus B<0.001, A versus C=0.020, B versus D=0.010, Ongoing pregnancy: A versus B<0.001, A versus C=0.012, B versus D=0.001. P=Progesterone, P/E2=Progesterone/estradiol ratio, BMI=Body mass index, AFC=Antral follicle count, AMH=Anti-Müllerian hormone, FSH=Follicle-stimulating hormone, SD=Standard deviation

Table 3: Association between ongoing pregnancy rate and serum progesterone or progesterone/estradiol ratio by multivariate logistic regression analysis

| Adjusted OR (95% CI) | P         |
|----------------------|-----------|
| P (ng/mL) (≥1.5 vs. <1.5) | 0.542 (0.284-1.036) | 0.064 |
| P/E2 (≥0.55 vs. <0.55) | 0.409 (0.222-0.753) | 0.004* |

*Statistically significant difference. The multivariate regression model included age, body mass index, antral follicle count, anti-Müllerian hormone, number of mature follicles, total gonadotrophins dose, number of oocyte retrieved, mature oocytes, number of good embryos obtained, and number of embryo transferred. P=Progesterone, P/E2=Progesterone/estradiol ratio, OR=Odds ratio, CI=Confidence interval

Discussion

Our study suggests that P elevation may not be an independent predictor for pregnancy outcome in GnRH antagonist cycle with day-3 ET. The study indicated that HP alone is not linked to adverse pregnancy outcomes; yet elevated P/E2 ratio on the ovulation triggering day is associated with a decrease in the ongoing pregnancy rate in the multivariate analysis.

Studying the value of adding P/E2 to serum P is of great importance to differentiate the P sources in different ovarian responders. In hyper-responder population, the HP levels might come from the cumulative production of a physiologic amount of P from the numerous growing follicles.[1] This should be differentiated from excess P secretion by a relatively low number of dysregulated follicles in patients with poor ovarian reserve.[20] The HP levels in patients with a poor ovarian reserve may originate from the intense stimulation with high-FSH.

gonadotrophins dose, number of oocyte retrieved, mature oocytes, triggering-day P level, number of good embryos obtained, and number of embryo transferred), the multivariate logistic regression model did not reveal any effect for peak E2 level on ongoing pregnancy (aOR: 1.0, P = 0.82).
Recent reports demonstrated a link between PL and embryo quality.6,22 Embryo utilization rate was significantly lower in patients with HP.7 Similarly, PL was related to a lower percentage of top-quality blastocysts formation.23 Our data demonstrated that PL based on P/E2 ≥0.55 and not on absolute P level is linked to a lower number of good quality day-3 embryos (5.0 ± 2.8 vs. 3.3 ± 2.5, P = 0.001, for high and low P/E2, respectively). Furthermore, the group of HP and HP/E2 had lower good embryos than that of HP only (P < 0.001). The same difference was observed in favor of low P and low P/E2 in comparison to HP/E2 only group (P < 0.001). Therefore, P/E2 ratio showed a better prognostic value for the increasingly-reported impact of PL on embryo quality.

Various risk factors were found to be linked to premature P elevation in the late follicular phase such as history of recurrent IVF failure and the patient’s profile including age, ethnicity, and BMI.4,5,33 The stimulation protocol, daily FSH dose, number of retrieved oocytes, peak estradiol level, total dose of gonadotropins, and stimulation days were assumed to be contributory for the chance of P elevation. The correlation analysis in our study revealed a positive association between P elevation and peak estradiol level, stimulation days, mature follicles, retrieved oocytes, and mature oocytes. Progesterone elevation had a weak inverse correlation, yet significant with BMI (R = −0.152, P = 0.002).

Embryo cryopreservation with deferring ETs is a widely accepted rescue strategy overcoming the PL-induced endometrial asynchrony. Nevertheless, embryo freezing represents an extra burden on the IVF laboratory and can be complicated by embryo losses during thawing.16 Therefore, identifying the accurate indicator and cutoff level for PL is important for the cost effective IVF management.

The association of peak estradiol (E2) level with pregnancy outcomes is conflicting. Some authors reported a positive correlation between peak E2 and number of oocytes retrieved, embryos allowed for transfer, adequate end thickens, and pregnancy outcomes.15-37 A retrospective study conducted by Kara et al.38 showed that the number of oocytes and clinical pregnancy are higher in patients with E2 ≥4000 pg/ml than those with E2 <4000 pg/ml. Peak E2 was not detrimental to the implantation rate, clinical pregnancy, or live birth rate.39 Other reports failed to draw a conclusion about the association between the supraphysiologic E2 level and pregnancy outcomes.40-42

The main limitation of this study is its retrospective design. The study being conducted in a single IVF

| Table 4: Correlations between progesterone levels and demographics and cycle characteristics |
|-------------------------------------------------|-----|-----|
| R                                              | P   |
| **Baseline characteristics**                   |     |
| Age                                            | 0.047 | 0.34 |
| BMI                                            | −0.152 | 0.002* |
| AFC                                            | 0.003 | 0.951 |
| AMH                                            | 0.042 | 0.405 |
| FSH                                            | 0.029 | 0.562 |
| LH                                             | 0.126 | 0.024* |
| **Cycle stimulation parameters**                |     |
| Peak estradiol level                           | 0.259 | <0.001* |
| Number of mature follicles                     | 0.123 | 0.014* |
| retrieved oocytes                              | 0.151 | 0.002* |
| Mature oocytes                                 | 0.129 | 0.009* |
| Number of embryos                              | 0.014 | 0.782 |
| Gonadotropins dose                             | 0.128 | 0.010* |
| Stimulation days                               | 0.098 | 0.051 |

*R statistically significant difference. BMI=Body mass index, AFC=Antral follicle count, AMH=Anti-Müllerian hormone, FSH=Follicle-stimulating hormone, LH=Luteinizing hormone.
center is another limitation on the size of data source. The difference regarding the number of embryos transferred in favor of the group with low P and low P/E2 can be initially considered a confounder in interpreting results. However, the multivariate regression analysis model accounted for the effect of various cycle covariates including the number of transferred embryos on ongoing pregnancy rate. The major strength of our study is the uniform stimulation protocol and day of ET. The pairwise comparison of all study subgroups added depth to identify the value of adding P/E2 to the P level in criticizing P elevation in the late follicular phase. The study results are significant also for the ongoing widely used shift in the ART practice in favor of the antagonist protocol.

**Conclusions**

Combining P/E2 to the absolute P level can assist the clinical decision for predicting the PL impact on pregnancy and embryological outcomes. Progesterone/estradiol ratio may be of high prognostic value for cycle outcomes when compared to serum P level alone. Thus, our study does not support the routine use of deferred ET in IVF cycles in cases of HP level ≥1.5 ng/ml that is currently practiced in IVF centers worldwide. Considering the retrospective design of the current study, more robust data are needed to endorse such a conclusion.

**Financial support and sponsorship**

This study was supported by the Assiut Faculty of Medicine grant’s office.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Venetis CA, Kolibianakis EM, Bosdou JK, Lainas GT, Sfountouris IA, Tarlatzis BC, et al. Estimating the net effect of progesterone elevation on the day of hCG on live birth rates after IVF: A cohort analysis of 3296 IVF cycles. Hum Reprod 2015;30:684-91.
2. Bosch E, Labarta E, Crespo J, Simón C, Remohí J, Jenkins J, et al. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: Analysis of over 4000 cycles. Hum Reprod 2010;25:2092-100.
3. Venetis CA, Kolibianakis EM, Bosdou JK, Tarlatzis BC. Progesterone elevation and probability of pregnancy after IVF: A systematic review and meta-analysis of over 60 000 cycles. Hum Reprod Update 2013;19:433-57.
4. Labarta E, Martínez-Conejero JA, Alamá P, Horcajadas JA, Pellicer A, Simón C, et al. Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: A functional genomics analysis. Hum Reprod 2011;26:1813-25.
5. Van Vaerenbergh I, Fatemi HM, Blockeel C, Van Lommel L, In’t Veld P, Schuit F, et al. Progesterone rise on hCG day in GnRH antagonist/FSH stimulated cycles affects endometrial gene expression. Reprod Biomed Online 2011;22:263-71.
6. Simon C, Moreau J, Gatimel N, Cohade C, Parinaud J, Leandri R. Impact of estradiol and progesterone levels during the late follicular stage on the outcome of GnRH antagonist protocols. Gynecol Endocrinol 2019;35:481-4.
7. Racca A, Santoro-Ribeiro S, De Munck N, Mackens S, Drakopoulos P, Camus M, et al. Impact of late-follicular phase elevated serum progesterone on cumulative live birth rates: Is there a deleterious effect on embryo quality? Hum Reprod 2018;33:860-8.
8. Kaponis A, Chronopoulou E, Decavallas G. The curious case of premature luteinization. J Assist Reprod Genet 2018;35:1723-40.
9. Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: A randomized assessor-blind controlled trial. Hum Reprod 2006;21:3217-27.
10. Kolibianakis EM, Albano C, Camus M, Tourmavey H, Van Steirteghem AC, Devroey P. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 2004;82:102-7.
11. Judd S, Terry A, Petrucco M, White G. The source of pulsatile secretion of progesterone during the human follicular phase. J Clin Endocrinol Metab 1992;74:299-305.
12. Al-Azem M, Kyrou D, Kolibianakis EM, Humaidan P, Van Vaerenbergh I, Devroey P, et al. Elevated progesterone during ovarian stimulation for IVF. Reprod Biomed Online 2012;24:381-8.
13. Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzis BC, Tourmavey H, Devroey P. Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial. Fertil Steril 2011;96:1112-5.
14. Manno M, Tomei F. Can we prevent premature luteinization in IVF cycles? Med Hypotheses 2014;82:122-3.
15. Hussein RS, Amin AF, Zhao Y, Abou-Taleb HA, Abdelmagied AM, Abdalameed OS, et al. Role of metformin in prevention of premature luteinization in fresh intracytoplasmic sperm injection (ICSI) cycles: A randomized controlled trial. Fertil Steril 2019;112:e57-8.
16. Hussein RS, Elnashar I, Amin AF, Abou-Taleb HA, Abbas AM, Abdelmageed AM, et al. Revisiting debates of premature luteinization and its effect on assisted reproductive technology outcome. J Assist Reprod Genet 2019;36:1-2.
17. Younis JS, Matilsky M, Radin O, Ben-Ami M. Increased progesterone/estriadiol ratio in the late follicular phase could be related to low ovarian reserve in in vitro fertilization-embryo transfer cycles with a long gonadotropin-releasing hormone agonist. Fertil Steril 2001;76:294-9.
18. Ozçakir HT, Levi R, Tavnergen E, Göker EN. Premature luteinization defined as progesterone estradiol ratio>1 on hCG administration day seems to adversely affect clinical outcome in long gonadotropin-releasing hormone agonist cycles. J Obstet Gynecol Res 2004;30:100-4.
19. Lai TH, Lee FK, Lin TK, Hong SG, Chen SC, Chen YH, et al. An increased serum progesterone-to-estradiol ratio on the day of human chorionic gonadotropin administration does not have a negative impact on clinical pregnancy rate in women with normal ovarian reserve treated with a long gonadotropin
20. Cetinkaya ES, Berker B, Aytaç R, Ateboglu C, Sonmez M, Ozmen B. The value of the progesterone-to-estradiol ratio on the day of hCG administration in predicting ongoing pregnancy and live birth rates in normoresponders undergoing GnRH antagonist cycles. European Journal of Obstetrics, Gynecology and Reproductive Biology 2013;170:452–457.

21. Elgindy EA. Progesterone level and progesterone/estradiol ratio on the day of hCG administration: Detrimental cutoff levels and new treatment strategy. Fertil Steril 2011;95:1639–44.

22. Huang B, Ren X, Wu L, Zhu L, Xu B, Li Y, et al. Elevated progesterone levels on the day of oocyte maturation may affect top quality embryo IVF cycles. PLoS One 2016;11:e0145895.

23. Vanni VS, Somigliana E, Reschini M, Pagliardini L, Marotta E, Faullisi S, et al. Top quality blastocyst formation rates in relation to progesterone levels on the day of oocyte maturation in GnRH antagonist IVF/ICSI cycles. PLoS One 2017;12:e0176482.

24. Liu L, Zhou F, Lin X, Li T, Tong X, Zhu H, et al. Recurrent IVF failure is associated with elevated progesterone on the day of hCG. Eur J Obstet Gynecol Reprod Biol 2013;171:78–83.

25. Aflatoonian D, Davar R, Hojjat F. Elevated serum progesterone/MII oocyte ratio on the day of human chorionic gonadotropin administration can predict impaired endometrial receptivity. Iranian journal of reproductive medicine. 2014;12:427.

26. Volpes A, Sammartano F, Coffaro F, Mistrutt V, Scaglione P, Allegra A. Number of good quality embryos on day 3 is predictive for both pregnancy and implantation rates in in vitro fertilization/intracytoplasmic sperm injection cycles. Fertil Steril 2004;82:1330-6.

27. Bungum L, Jacobsson AK, Rosen F, Becker C, Yding Andersen C, Güner N, et al. Circadian variation in concentration of anti-Müllerian hormone in regularly menstruating females: Relation to age, gonadotrophin and sex steroid levels. Hum Reprod 2011;26:678-84.

28. Younis JS, Haddad S, Matlisky M, Ben-Ami M. Premature luteinization: Could it be an early manifestation of low ovarian reserve? Fertil Steril 1998;69:461-5.

29. Younis JS, Ben-Shlomo I, Ben-Ami M. Premature luteinization defined by an increased progesterone/estradiol ratio on day of human chorionic gonadotropin administration is a manifestation of diminished ovarian responsiveness to controlled ovarian hyperstimulation. Fertil Steril 2010;93:e29.

30. Arora R, Chan C, Ye XY, Greenblatt EM. Progesterone, progesterone/estradiol and ART outcomes in day-5 transfer cycles. Gynecol Endocrinol 2018;34:59-63.

31. Lee FK, Lai TH, Lin TK, Horng SG, Chen SC. Relationship of progesterone/estradiol ratio on day of hCG administration and pregnancy outcomes in high responders undergoing in vitro fertilization. Fertil Steril 2009;92:1284-9.

32. Golbasi H, Ince O, Golbasi C, Ozer M, Demir M, Yilmaz B. Effect of progesterone/estradiol ratio on pregnancy outcome of patients with high trigger-day progesterone levels undergoing gonadotropin-releasing hormone antagonist intracytoplasmic sperm injection cycles: A retrospective cohort study. J Obstet Gynecol 2019;39:157-63.

33. Cetinkaya ES, Berker B, Aytaç R, Ateboglu C, Sonmez M, Ozmen B. The value of the progesterone-to-estradiol ratio on the day of hCG administration in predicting ongoing pregnancy and live birth rates in normoresponders undergoing GnRH antagonist cycles. Eur J Obstet Gynecol Reprod Biol 2013;170:452-7.

34. Seow KM, Lin YH, Hsieh BC, Huang LW, Huang SC, Chen CY, et al. Characteristics of progesterone changes in women with subtle progesterone rise in recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonist cycle. Gynecol Obstet Invest 2010;70:64-8.

35. Wei M, Zhang XM, Gu FL, Lv F, Ji YR, Liu KF, et al. The impact of LH, E2, and P level of hCG administration day on outcomes of in vitro fertilization in controlled ovarian hyperstimulation. Clin Exp Obstet Gynecol 2015;42:361-6.

36. Siddhartha N, Reddy NS, Pandurangi M, Tamizharasi M, Radha V, Kanimozhi K. Correlation of serum estradiol level on the day of ovulation trigger with the reproductive outcome of intracytoplasmic sperm injection. J Hum Reprod Sci 2013;6:23-7.

37. Rehman R, Jawaid S, Gul H, Khan R. Impact of peak estradiol levels on reproductive outcome of intracytoplasmic sperm injection. Pak J Med Sci 2014;30:986-91.

38. Kara M, Kutlu T, Sofooglu K, Devranoglu B, Cetinkaya T. Association between serum estradiol level on the hCG administration day and IVF-ICSI outcome. Iran J Reprod Med 2012;10:53-8.

39. Wang M, Hao C, Bao H, Huang X, Liu Z, Zhang W, et al. Effect of elevated estradiol levels on the hCG administration day on IVF pregnancy and birth outcomes in the long GnRH-agonist protocol: Analysis of 3393 cycles. Arch Gynecol Obstet 2017;295:407-14.

40. Imudia AN, Goldman RH, Awonuga AO, Wright DL, Styer AK, Toth TL. The impact of supraphysiologic serum estradiol levels on peri-implantation embryo development and early pregnancy outcome following in vitro fertilization cycles. J Assist Reprod Genet 2014;31:65-71.

41. Wu Z, Li R, Ma Y, Deng B, Zhang X, Meng Y, et al. Effect of HCG-day serum progesterone and oestradiol concentrations on pregnancy outcomes in GnRH agonist cycles. Reprod Biomed Online 2012;24:511-20.

42. Kyrou D, Popovic-Todorovic B, Fatemi HM, Bourgain C, Haentjens P, Van Landuyt L, et al. Does the estradiol level on the day of human chorionic gonadotrophin administration have an impact on pregnancy rates in patients treated with rec-FSH/GnRH antagonist? Hum Reprod 2009;24:2902-9.